Michael Nofi - 10 Nov 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: EWTX
Reported as of: 10 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Nov 2025, 18:03:07 UTC
Prior SEC filing: 02 Jul 2025
Next SEC filing: 17 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ John R. Moore, Attorney-in-Fact for Michael Nofi

Key filing fact

Michael Nofi filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 13 Nov 2025.

Key facts

This page summarizes Michael Nofi's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Nov 2025, 18:03.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001705477 Primary reporting owner

Nofi Michael

Relationship: Chief Financial Officer
Address: 1715 38TH STREET, BOULDER
Signature: /s/ John R. Moore, Attorney-in-Fact for Michael Nofi
Signature date: 13 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +43,750
Change %
Price: $0.000000
Shares after: 43,750
Date: 10 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,750
Exercise price: $0.000000
Footnotes: F1

EWTX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +262,500
Change %
Price: $0.000000
Shares after: 262,500
Date: 10 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 262,500
Exercise price: $18.28
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

Footnote F2

1/4th of the shares subject to the option become vested and exercisable on November 10, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.